Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Finke, Jürgen  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Radujkovic A, Dietrich S, Blok H-J, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, et al. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors - A retrospective study by the EBMT Chronic Malignancies Working Party. Biol Blood Marrow Transplant. 2019.
Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016;374(1):43-53.
B
Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, et al. Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
C
Shimoni A, Labopin M, Savani B, Byrne M, Volin L, Finke J, Niederwieser D, Ehninger G, Blaise D, Beelen D, et al. Comparable Long-Term Outcome after Allogeneic Stem-Cell Transplantation from Sibling and Matched Unrelated Donors in AML Patients Older than 50 years. A Report on Behalf of the ALWP of EBMT. Biol Blood Marrow Transplant. 2019.
Lee CJ, Labopin M, Beelen D, Finke J, Blaise D, Ganser A, Itälä-Remes M, Chevallier P, Labussière-Wallet H, Maertens J, et al. Comparative Outcomes of Myeloablative and Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Therapy-Related Acute Myeloid Leukemia with Prior Solid Tumor: a report from the ALWP of the EBMT. Am J Hematol. 2018.
Brand R, Putter H, van Biezen A, Niederwieser D, Martino R, Mufti G, Onida F, Symeonidis A, Schmid C, Garderet L, et al. Comparison of Allogeneic Stem Cell Transplantation and Non-Transplant Approaches in Elderly Patients with Advanced Myelodysplastic Syndrome: Optimal Statistical Approaches and a Critical Appraisal of Clinical Results Using Non-Randomized Data. PLoS One. 2013;8(10):e74368.
Duque-Afonso J, Finke J, Labopin M, Craddock C, Protheroe R, Kottaridis P, Tholouli E, Byrne JL, Orchard K, Salmenniemi U, et al. Comparison of fludarabine-melphalan and fludarabine-treosulfan as conditioning prior to allogeneic hematopoietic cell transplantation-a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplant. 2022.
D
Sommer S, Cruijsen M, Claus R, Bertz H, Wäsch R, Marks R, Zeiser R, Bogatyreva L, Blijlevens NMA, May A, et al. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation. Leuk Res. 2018;72:20-26.
Waterhouse M, Pfeifer D, Duque-Afonso J, Follo M, Duyster J, Depner M, Bertz H, Finke J. Droplet digital PCR for the simultaneous analysis of minimal residual disease and hematopoietic chimerism after allogeneic cell transplantation. Clin Chem Lab Med. 2018.
E
Chalandon Y, Passweg JR, Guglielmi C, Iacobelli S, Apperley J, Schaap NPM, Finke J, Robin M, Fedele R, Bron D, et al. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT. Haematologica. 2014.
F
Rodríguez-Arbolí E, Labopin M, Tischer J, Brecht A, Ganser A, Finke J, Blau IWolfgang, Kröger N, Kalhs P, Forcade E, et al. FLAMSA-based reduced intensity conditioning versus myeloablative conditioning in younger patients with relapsed/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an ALWP/EBMT analysis. Biol Blood Marrow Transplant. 2020.
G
Mathew NR, Vinnakota JM, Apostolova P, Erny D, Hamarsheh S'a, Andrieux G, Kim J-S, Hanke K, Goldmann T, Chappell-Maor L, et al. Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia. J Clin Invest. 2019.
H
Robin M, Porcher R, Ruggeri A, Blaise D, Wolschke C, Koster L, Angelucci E, Stölzel F, Potter V, Yakoub-Agha I, et al. HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis. Biol Blood Marrow Transplant. 2018.
I
Duque-Afonso J, Ihorst G, Waterhouse M, Zeiser R, Wäsch R, Bertz H, Müller-Quernheim J, Finke J, Marks R, Prasse A. Impact of lung function on bronchiolitis obliterans syndrome and outcome after allogeneic hematopoietic cell transplantation with reduced intensity conditioning. Biol Blood Marrow Transplant. 2018.
Duque-Afonso J, Ewald S, Ihorst G, Waterhouse M, Strüessmann T, Zeiser R, Wäsch R, Bertz H, Müller-Quernheim J, Duyster J, et al. The impact of pulmonary function in patients undergoing autologous stem cell transplantation. Blood Adv. 2021.
L
Gagelmann N, Bogdanov R, Stölzel F, Rautenberg C, Panagiota V, Becker H, Radujkovic A, Luft T, Christopeit M, Finke J, et al. Long-term survival benefit after allogeneic hematopoietic cell transplantation in chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2020.
O
Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, et al. OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT. Biol Blood Marrow Transplant. 2019.
P
Javorniczky NRebeka, Wehrle J, Ihorst G, Hupfer V, Aumann K, Pfeifer D, Niemöller C, Bleul S, Pantic M, Werner M, et al. Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. Leuk Res. 2020;98:106454.
S
Kharfan-Dabaja MA, Labopin M, Brissot E, Kröger N, Finke J, Ciceri F, Deconinck E, Blaise D, Chevallier P, Gramatzki M, et al. Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. Br J Haematol. 2021.
Nagler A, Labopin M, Dholaria B, Finke J, Brecht A, Schanz U, Niittyvuopio R, Neubauer A, Bornhäuser M, Santarone S, et al. Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2019.
Christopeit M, Kuss O, Finke J, Bacher U, Beelen DWilhelm, Bornhäuser M, Schwerdtfeger R, Bethge WAndreas, Basara N, Gramatzki M, et al. Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change. J Clin Oncol. 2013.
T
Brissot E, Labopin M, Beckers MM, Socié G, Rambaldi A, Volin L, Finke J, Lenhoff S, Kröger N, Ossenkoppele GJ, et al. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica. 2014.
U
Ruggeri A, Battipaglia G, Labopin M, Ehninger G, Beelen D, Tischer J, Ganser A, Schwerdtfeger R, Glass B, Finke J, et al. Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT study. J Hematol Oncol. 2016;9(1):89.